Recipharm, the contract development and manufacturing organization (CDMO), has established a dedicated taskforce to manage the potential impact of Brexit on its organization.
With less than a year until the U.K. exits the European Union (EU), the Sweden headquartered global CDMO is focused on managing the transition with minimal impact to its operations and customers.
The formation of the ‘Brexit taskforce’ will see Recipharm prioritize its preparations and invest in the necessary capabilities and equipment within its U.K. and European facilities to ensure seamless operations post March 2019.
“While many stakeholders in the pharma industry are campaigning for a ‘soft’ exit from the EU, there is a risk that the complexity of the regulatory landscape will increase dramatically if a ‘hard’ Brexit takes place,” Thomas Beck, senior vice president, quality management at Recipharm, said. “Recipharm’s presence in both the U.K. and mainland Europe means we are well positioned to support our customers post-Brexit.”
To strengthen its organization ahead of Brexit, Recipharm said it has plans to recruit more staff in laboratory and regulatory roles to meet the additional analytical, release testing, and administration requirements that are expected.
“We are focused on ensuring our team is equipped to handle the potential challenges so that our customers continue to receive the same level of service,” Thomas continued. “We also expect to see a greater demand for outsourced manufacturing services from U.K.-based marketing authorization holders (MAHs) wishing to supply to Europe and are preparing our team to meet this demand.”
Recipharm serves 450+ customers from development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the U.K., and the U.S.
(Source: Recipharm)
